Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2011

View Archived Issues

Phase III data on rivaroxaban in subjects with acute coronary syndromes

Human monoclonal antibodies show anticancer potential in preclinical and clinical settings

TMED10 gene SNP linked to Alzheimer's disease

Patrys raises funds to support anticancer pipeline

Medicis completes acquisition

U3-1287 combinations assessed in lung and pharynx cancer

Kowa identifies new cholesterol ester transfer protein inhibitors

New triterpenoid derivatives prepared by Concert Pharmaceuticals

Purdue exercises option to commercialize Intermezzo

Novel GPR119 receptor agonists disclosed by Bristol-Myers Squibb

Infinity Pharmaceuticals patents novel fatty acid synthase inhibitors

Zalicus begins phase I study of new Z-160 formulation

Spectrum Pharmaceuticals files IND with FDA for phosphate-binding agent

Scientists at Merck & Co. synthesize new fatty-acid amide hydrolase inhibitors

Belgian university discloses novel Amaryllidaceae isocarbostyryl derivatives for cancer

New 11-beta-HSD1 inhibitors patented in Korea

Targacept launches two new clinical studies of TC-5619

Pfizer finalizes acquisition

AtheroNova and Maxwell Biotech ratify agreement for AHRO-001

Oncolytics Biotech reports on Reolysin in pancreatic cancer

Achillion discloses preliminary proof-of-concept data on ACH-2928 and advances ACH-3102

Pivotal trial of cobicistat meets primary endpoint

ViroPharma and Halozyme report topline data from hereditary angioedema study

Second milestone reached in GenVec/Novartis collaboration

FDA accepts Cell Therapeutics' resubmission of pixantrone NDA as complete

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.